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Introduction
Human sexually transmitted infections are prevalent
throughout the world. Several have been associated with
adverse pregnancy outcome and increased susceptibility
to HIV infection, in addition to the discomfort of inflam-
mation of the genital tract. Yet vaccines to protect against
the infection at the genital mucosa are not available. Hep-
atitis B is an exception, but this virus becomes systemic
and protection may be at the systemic level. Sexually
transmitted diseases (STDs) have long been associated
with reproductive failure in cattle. These infections cause
considerable economic loss, which has been a stimulus to
investigation. Consequently, vaccines and mechanisms of
immune protection have been studied quite thoroughly.
The results obtained with two commercially available vac-
cines will be used to illustrate principles of protective
immunity against STDs. Both Campylobacter fetus subsp.
venerealis and Tritrichomonas foetus are only transmitted
sexually and both cause reproductive failure in cattle.
Campylobacter fetus subsp. venerealis Vaccines
Although the work on C. fetus was done several decades
ago, a brief review is included here because several impor-
tant principles were first defined with this vaccine. Campy-
lobacter fetus subsp. venerealis (formerly Vibrio fetus) is a
microaerophilic gram negative motile curved bacterium.
The organism is an extracellular noninvasive pathogen so
antibody is critical to protection. This was demonstrated
by Berg et. al. [1], who passively protected heifers against
experimental intravaginal infection with C. fetus by sys-
temic administration of immune serum. Since antibody
was protective, little research has been done on cell medi-
ated immunity (CMI). Sexual transmission results in gen-
ital campylobacteriosis, a chronic infection of the female
reproductive tract which lasts several months. Clinical
signs are minimal, with the exception of fetal loss or
apparent infertility (perhaps due to early embryonic loss).
The male is an asymptomatic carrier and thus is a constant
source of transmission. In female cattle, convalescent
immunity is partially protective. Cows becoming re-
infected within 2 years of clearing the infection are pro-
tected against reproductive failure, but do become vaginal
carriers. This partial immune protection was seen as evi-
dence that enhancement of immunity may result in total
clearance of infection. Studies of mechanisms of convales-
cent immunity were undertaken as a basis for designing
vaccines [2,3]. Infected animals had early and long lasting
surface specific IgA antibody responses in vaginal secre-
tions [4]. These antibodies remained at high levels until
the end of the experiment (20–30 weeks after vaginal cul-
tures were negative for C. fetus). IgG antibody responses
were detectable later and waned much earlier. Although
IgA antibodies predominated in vaginal secretions
throughout infection, antibodies in uterine secretions
(collected at necropsy at 7–9 months post-infection) were
primarily of the IgG1 subclass [4,5]. Since the uterus is
usually cleared of the infection before the vagina [2], it
appeared that IgG1 was more protective than IgA anti-
body to surface antigen. Therefore, heifers (sexually
mature animals which had never been with a bull, so were
not exposed to STDs) were systemically immunized with
whole formalized cells of C. fetus in (complete Freund's
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Adjuvant (CFA). Only IgG1 and IgG2 antibodies to C.
fetus were detected in vaginal and uterine secretions [2].
Since animals immunized with this procedure were resist-
ant to colonization by C. fetus [2], the IgG response elic-
ited by systemic mmunization appeared to be more
protective than convalescent immunity. In vitro functional
studies [5] showed that neither IgG nor IgA antibodies to
surface antigens mediated killing of the virulent strain by
bovine complement, although a rough strain was killed
(positive complement control). IgA antibodies immobi-
lized C. fetus better than IgG antibodies at a standardized
agglutination titer. Conversely, IgG antibodies mediated
opsonization and intracellular killing of C. fetus by mac-
rophages [5] and neutrophils [6], whereas IgA antibodies
did not.
Interestingly, in experimentally infected heifers, the infec-
tion lasts from 4 to10 months in the face of a robust anti-
body response [2,3]. Mechanisms of evasion of this
immune response were addressed by infecting heifers
intravaginally with a C. fetus inoculum that had been
cloned by limiting dilution. Isolates from periodic sam-
plings over the course of infection (120 to 219 days)
exhibited marked antigenic variation [7]. This evasive
mechanism was thought to account for the chronicity of
the infection. Even with effective antigenic variation, sys-
temic vaccination with formalized C. fetus in CFA, 14 and
24 days after experimental infection was shown to cure
the infection [8]. Antigenic variation was detected before
the infection was cleared, but the high antibody levels in
genital secretions were correlated with termination of
infection shortly after the second vaccination in most heif-
ers. This illustrates the dynamic interaction between the
microbe's evasive mechanism and the protective immune
responses of the host. Antigenic variation results in eva-
sion until the host response catches up with the specificity
and magnitude necessary to clear infection. The studies of
immunity to C. fetus provide the basis for understanding
the mechanisms by which vaccines for this sexually trans-
mitted bovine infection protect. These vaccines have been
available for several decades and have controlled the dis-
ease in parts of the world where they are used.
Tritrichomonas foetus Vaccines
Trichomoniasis is a human and bovine sexually transmit-
ted disease. Other animal species do not have STDs caused
by trichomonads, as far as is known. Human trichomo-
niasis is caused by Trichomonas vaginalis and bovine tri-
chomoniasis is caused by Tritrichmonas foetus. Both are
motile anerobic protozoan pathogens which colonize the
epithelial surface in the genital tract. Like C. fetus, T. foetus
is an extracellular pathogen, so antibody on the mucosal
surface should be most critical for protection. Undoubta-
bly CMI plays a role also, but this has not been well stud-
ied. Bovine trichomoniasis, like the C. fetus infection,
results in reproductive failure. Fetal loss occurs most often
late in the first trimester or early in second trimester,
although late term abortions are also seen. Since this is the
only known animal to have a naturally occurring STD due
to trichomonads, it serves as a model of human trichomo-
niasis. The human infection is also associated with
adverse outcome of pregnancy, including preterm birth,
premature rupture of the membranes and low birth
weight infants [9-12]. Little information is available on
the role of T. vaginalis in human pregnancy loss at the end
of the first/beginning of the second trimester (spontane-
ous abortion). Human trichomoniasis is similar to the
bovine infection in that only sexual transmission occurs,
the chronic infection is limited to the mucosal surface,
and asymtomatic carriers occur among females and pre-
dominate among males. Vaccines protective against the
bovine infection may provide clues for protection against
human trichomoniasis and other STDs.
Protective antigen(s)
In order to identify virulence factors of T. foetus which
may be targets for protective immune responses, we first
prepared a bank of monoclonal antibodies (mAbs) [13].
Two surface reactive mAbs (TF1.15 and TF1.17) were
shown to have functions which correlate with protection
(agglutination, immobilization, inhibition of adherence
Table 1: Summary of key information on protective immunity in bovine genital campylobacteriosis and trichomoniasis.
Characteristic Campylobacteriosis Trichomoniasis
Etiologic Agent C. fetus (Gram negative bacteria) T. foetus (Protozoa)
Parasitic Type Extracellular noninvasive Extracellular noninvasive
Passive Protection by Antibody Reference 1 ND*
Specificity of Protective Antibody Heat labile surface antigen (S-Layer – Reference 33) Lipophosphoglycan surface antigen
Predominant Ig Class of Protective Antibody Uterus IgG1 or IgG2 Vagina IgA or IgG1 Uterus IgG1 Vagina IgA or IgG1
Most Protective Immunization Systemic Systemic or Systemic priming and local boosting
Cure of Infection by Vaccination Male and Female Male (Female?)
Evasion of Host Responses Antigenic Variation Proteinase cleavage of Ig Nonspecific binding of Ig
Vaccines Available Commercially Whole killed cells Systemic route Whole killed cells Systemic route
*ND = Not Done
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to vaginal epithelial cells and complement mediated kill-
ing). These mAbs recognize different epitopes on the same
highly glycosylated antigen, which was conserved among
all isolates tested [14]. The antigen was then immunoaf-
finity purified with TF1.17 mAb and designated TF1.17
antigen. Further studies showed it to be a lipophosphogly-
can (LPG)/protein complex [15]. A soluble form of the
antigen is released from the surface (soluble glycosylated
antigen or SGA). Both T. foetus and T. vaginalis have ~106
molecules of LPG per cell [16], so it is a major antigen of
both pathogens.
Protective immune responses
Convalescent immunity is partially protective against T.
foetus as with C. fetus. We studied this response in order
to understand how to enhance protection by vaccination.
Skirrow and BonDurant [17] showed that clearance of
vaginal infection occurred when antibodies to whole tri-
chomonads increased in vaginal secretions. There was lit-
tle detectable systemic antibody response. Later studies
showed that IgG1 and IgA antibodies correlated with
clearance of the vaginal infection [18]. Only IgG1 and IgA
antibody to TF1.17 antigen (LPG/protein complex) were
detected in uterine secretions also [19]. IgG1 is a Th2 type
response in cattle [20], so it may be that this antigen
induces a very skewed response. The production of any
local immune response to genital tract infection raised a
question since a mucosally associated lymphoid tissue is
not seen in histologic sections, especially in the uterus.
Histopathologic studies of reproductive tracts of experi-
mentally infected heifers, however, showed lymphoid
accumulations under the uterine surface and glandular
epithelium [19,21,22]. This was especially true around
infected glands. Some lymphoid nodules even had germi-
nal centers (Figure 1). Plasma cells below the glandular
epithelium (Figure 2) were consistent with secretion of
antibodies across the uterine epithelium. Subsequent
immunohistochemical studies, with mAbs specific for T.
foetus LPG, demonstrated antigen uptake by uterine epi-
thelial cells (Figure 3). This figure also demonstrates
abundant intraepithelial and subepithelial lymphocytes,
suggesting recruitment of immune cells. We have detected
similar lymphoid nodules and antigen uptake in the vag-
inal mucosa of heifers (Rhyan, BonDurant and Corbeil,
unpublished data) and the preputial epithelium of bulls
[25] infected with T. foetus. Both bulls and heifers had IgA
responses in genital secretions [18,19,21,22,25]. Others
[23] have shown that both human uterine epithelial and
stromal cells can present antigen to T cells. This same
research group has also demonstrated lymphoid nodules
in human uterine epithelium [24]. Therefore, it can be
concluded that cells taking up antigen likely present that
antigen to T helper cells, that antigenic stimulation leads
to the formation of mucosally associated lymphoid tissue
in the genital tract and that IgA responses result.
The association of mucosal IgA and IgG1 antibody
responses to TF1.17 antigen indicated that it was a candi-
date for a subunit vaccine. Several studies showed that sys-
temic immunization with immunoaffinity purified
TF1.17 antigen cleared the infection, usually before 7
weeks [18,19,21,22]. Controls cleared several weeks later.
Earlier Parsonson et. al. [26] had shown that before 8
Histopathologic section of the endometrium of a heifer 12 weeks fter experimental infection with 106 T. foetus at estrusFigure 1
Histopathologic section of the endometrium of a heifer 12 
weeks after experimental infection with 106 T. foetus at 
estrus. Note the periglandular lymphoid nodule with appar-
ent germinal centers. Stained with haematoxylin and eosin.
Higher magnification of Figure 1, showing plasma cells below the uterine glandular epitheliumFi r  2
Higher magnification of Figure 1, showing plasma cells below 
the uterine glandular epithelium.
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weeks of infection there was no fetal loss and little inflam-
mation in the reproductive tract or placenta of T. foetus
infected pregnant heifers. Heifers aborted if they had not
cleared the infection by 8 weeks. Thus, in this chronic
infection, clearance before 8 weeks should protect against
disease (reproductive failure). Studies with whole cell vac-
cines have demonstrated that immunized heifers and
cows do have higher pregnancy rates [27]. The role of IgA
vs. IgG1 in protection was not clear from these studies,
however. IgA is usually thought to be the major Ig class in
protection of mucosal surfaces, but both IgA and IgG1
pathogen specific antibodies were found in vaginal secre-
tions in both the local immune response of infected heif-
ers and after systemic immunization [18]. To determine
which was more protective, we first immunized mice
using several different routes and adjuvants to enrich for
either IgA or IgG antibodies to TF1.17 antigen in genital
secretions [21]. Systemic priming with TF1.17 antigen and
local vaginal boosting with whole trichomonads gave the
greatest IgA anti-TF1.17 levels in genital secretions
whereas systemic priming and boosting with these anti-
gens in the same adjuvant (Quil A) greatly enriched for
IgG antibodies. These two regimens then were used in vir-
gin heifers, followed by challenge with the standard dose
of T. foetus intravaginally to test protection. The vaginally
boosted group did have primarily IgA antibodies to
TF1.17 antigen in vaginal secretions and the systemically
boosted group had primarily IgG1 antibodies. Both
groups cleared the infection earlier than controls (p <
0.05), mostly before 7 weeks, as in earlier studies. There
was no significant difference between the two immunized
groups. Since the specificity of both Ig classes was the
same, this indicates that IgG1 and IgA antibodies are both
protective.. To determine whether the common mucosal
immune system could be employed to protect the genital
tract in this infection, we then repeated the experiment,
but with local intranasal boosting rather than intravaginal
boosting [22]. Again, IgA antibodies predominated in
vaginal secretions of the locally boosted groups and IgG1
antibodies predominate in the systemically boosted
group. Both were cleared faster than nonimmunized con-
trols (p < 0.05) but there was no significant difference
between locally and systemically boosted immunized
groups [22]. It is apparent that both intranasal and intra-
vaginal immunization results in secretion of IgA antibod-
ies into vaginal secretions and that either IgA or IgG1
specific TF1.17 antibodies is equally protective. In addi-
tion to successful immunization of cows against
trichomoniasis, it has been shown that systemic vaccina-
tion of bulls with whole trichomonads or partially paci-
fied glycosylated membrane antigens also protects against
chronic infection [31]. Notably, systemic vaccination with
these antigens has been reported to cure infected bulls
[32]. Thus, systemic immunization can protect against T.
foetus induced disease and can cure long term infection.
Mechanisms of transport of immunglobulins
The mechanism of transport of antibodies into the genital
secretions is of some interest. It has been known for some
time that IgA is transported across the epithelium via the
Poly-Ig receptor. However, the mechanism of transport of
IgG1 across the epithelium is not well understood. Pre-
liminary data from our lab indicates that mast cells and
IgE antibody responses to TF 1.17 antigen may be
involved (Corbeil LB, BonDurant RH, Campero CM and
Gerswin LJ, unpublished data). The need for an IgE
response to allow IgG1 antibodies to be transported to
genital secretions may be partially responsible for the
delay in appearance of IgG1 antibodies in these
secretions.
Mechanisms of immune evasion
Tritrichomonas foetus, like C. fetus, has mechanisms to
evade the host response. The parasite binds IgG to its sur-
face nonspecifically [28], which provides a means of self-
recognition. This may be a factor in the delayed inflam-
mation and local immunity by masking of antigens to
evade stimulation of responses. Furthermore, T. foetus
(like T. vaginalis) secretes cysteine proteinase which
cleaves IgG1, IgG2, fibronectin, fibrinogen and lactoferrin
[29] as well as C3 [30]. The first mechanism (Ig binding)
may avoid stimulation of immune responses and the
second (proteinase digestion) likely destroys potentially
protective innate and acquired responses. In spite of this,
Immunohistochemistry of the surface endometrial epithelium of a heifer 6 we ks after experimental infection with 106 T. foetus at e rusFig r  3
Immunohistochemistry of the surface endometrial epithelium 
of a heifer 6 weeks after experimental infection with 106 T. 
foetus at estrus. Stained with mAb TF1.15 (specific for TF 
1.17 antigen) and developed with peroxidase conjugate. Note 
the antigen uptake by epithelial cells with intense staining at 
the apical surface. Intraepithelial plus subepithelial lym-
phocytes are also detected.
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however, local immunity eventually clears the infection
and local or systemic vaccination with appropriate anti-
gens and adjuvants can enhance the response enough to
clear infection before inflammation and reproductive fail-
ure result.
Conclusions
In both C. fetus and T. foetus infection of the bovine
female genital tract, convalescent immunity associated
with mucosal IgA antibody is partially protective.
Systemic immunization clears the chronic infection early
enough to prevent adverse outcome of pregnancy in both
infections. Studies with trichomoniasis showed that anti-
gen uptake by the genital epithelium is followed by for-
mation of mucosally associated lymphoid tissue. A local
IgA and IgG1 response results. Either IgA or IgG1 antibod-
ies are equally protective. Mechanisms of transport of
IgG1 antibodies into mucosal secretions needs to be
defined. Since systemic immunization protects in both
bovine trichomoniasis and genital campylobacteriosis, it
may be protective against other extracellular pathogens
causing STDs in other animal species and in humans. It
may be even more protective against pathogens which
invade across the genital mucosa becoming more accessi-
ble to systemic immune responses.
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